ASX Announcements

2021

23 November 2021 – Entitlement Offer extension

15 November 2021 – Notice of Meeting & Proxy Form

5 November 2021 – Prospectus

5 November 2021 – Application for Quotation of Securities – Appendix 2A

5 November 2021 – Placement & Cleansing Notice

1 November 2021 – Investor Presentation 1 Nov 2021

1 November 2021 – Appendix 3B

1 November 2021 – Positive PDCO Opinion & $20M Placement

29 October 2021 – 2021 Annual Report

29 October 2021 – Appendix 4G & Governance Statement 2021

29 October 2021 – Quarterly Update and Apendix 4C

4 October 2021 – Antisense Therapeutics appoints new Non-Executive Director

30 September 2021 – Positive feedback received on Paediatric Investigation Plan

24 September 2021 – Statistically significant modulation in two DMD disease modifier proteins supports potential of ATL1102 in ambulant DMD and fibrotic conditions

20 September 2021 – New ATL1102 proteomics data to be presented in a Late Breaking News Abstract at the World Muscle Society 2021 Virtual Congress

25 August 2021 – Appendix 4E – Audited Financial Report Year Ended 30 June 2021

24 August 2021 –  ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA

12 August 2021 – ANP Updates on US Regulatory Plans for ATL1102 in DMD

28 July 2021 –Antisense Therapeutics transitions to new Board Chair

28 June 2021 – Antisense Therapeutics and Murdoch Children’s Research Institute enter into new R&D collaboration to further explore ATL1102 use in multiple muscle diseases

22 June 2021 – ATL1102 for DMD EMA PIP feedback and FDA regulatory progress

1 June 2021 –  US FDA Feedback on Type C Meeting for ATL1102 in the US

26 May 2021 – Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD

28 April 2021 – Quarterly Report & Appendix 4C_March 2021

23 April 2021 – ATL1102 FDA Type C meeting

24 March 2021 – Director’s Initial Interest Notice

22 March 2021 – Appointment of new Non-Executive Director

19 March 2021 – Appendix 3G

4 March 2021 – FDA Rare Disease Day

26 February 2021 – Jett Foundation Rare Disease Day

25 February 2021 – Paediatric Investigation Plan for ATL1102 in DMD submitted to European Medicines Agency

24 February 2021 – Appointment of Joint Company Secretary

24 February 2021 – Half Yearly Report and Half Year Accounts

15 February 2021 – Antisense Therapeutics granted Type C meeting with US FDA for ATL1102 in DMD

28 January 2021 – Appendix 4C & Quarterly Report_31 Dec 20 QTR_Final

2020

European Commission grants Orphan Drug Designation for ATL1102 in DMD

ANP to present at Several Upcoming Virtual Conferences

ANP closes SPP oversubscribed

ANP to present at Australian Equities Day

ANP Dual Lists on the Frankfurt Stock Exchange

ANP Share Purchase Plan Booklet

Notice of Annual General Meeting

Appendix 2A & Cleansing Notice

Antisense Therapeutics Limited raises A$7.3 million in oversubscribed Placement

Proposed Issue of Securities

ANP receives positive opinion from EMA on Orphan Drug Designation for ATL1102 in Duchenne muscular dystrophy (DMD)

Antisense Therapeutics Limited raises A$7.3 million in oversubscribed Placement

ANP to apply for dual listing on Frankfurt Stock Exchange

ANP receives US FDA Orphan Drug Designation for ATL1102 for the treatment of DMD

Quarterly Report & Appendix 4C

Statistically significant improvement in PUL2.0 with ATL1102 treatment in non-ambulant boys with DMD compared to a matched natural history control

US FDA Grants Rare Pediatric Disease Designation to ATL1102 for the treatment of DMD

New ATL1102 data to be presented at the 25th International Annual Congress of the World Muscle Society

ANP Submits EMA Orphan Drug Application for ATL1102 in DMD

Appendix 4E & Full Year Statutory Accounts

ANP Submits US FDA Orphan Drug Application for ATL1102 in DMD

Quarterly Update & Appendix 4C

EMA DMD Scientific Advice and Regulatory Process Update

ANP to Participate at 2020 PPMD Virtual Annual Conference

Sharecafe Small Cap “Hidden Gems” Webinar Presentation

Antisense Therapeutics to Present at Webinar Hosted by Parent Project Muscular Dystrophy in the US

Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints

Market Update

Antisense to Present at NWR Virtual Health Conference

Quarterly Update and Appendix 4C

ATL1102 Phase II DMD trial database lock and final results on track

ATL1102 Phase II DMD trial data to be presented at Duchenne ACTT Now Conference

App 4D – Half yearly report and half yearly accounts

Appointment of US-based Consultant Medical Director

Results in DMD unlock value creation potential of ATL1102

Appendix 4C – Quarterly Report

Appointment of new Non-Executive Director

Presentation for SACHS 3rd Neuroscience Innovation Forum

ANP to Present at Neuroscience Innovation Forum in the US

Listed Options Raise $5.5M

Appendix 3B & 708A Notice

2019

Change of Directors Interest Notice (RM, MD, GM, GP, WG)

Appendix 3B – 23 Dec 2019

Change of Directors Interest Notice (WG)

Change of Directors Interest Notice (RM)

Appendix 3B – 19 Dec 2019

Change of Directors Interest Notice (RM)

Change of Directors Interest Notice (MD)

Change of Directors Interest Notice (GM)

Appendix 3B – 18 Dec 2019

Positive Results reaffirm plans to advance ATL1102 to Phase IIb

Underwriting of Listed Options

Change of Directors Interest Notice (RM)

Appendix 3B – 16 Dec 2019

Results of AGM

AGM Presentation December 2019

Change of Directors Interest Notice (RM)

Appendix 3B – 04 Dec 2019

Appendix 3B – 25 Nov 2019

Dosing Completed in ATL1102 Phase II DMD trial

Additional ATL1102 trial data presented at DMD UK conference

Expiry of Listed Options

Antisense Therapeutics Listed Option Exercise

Appendix 3B – 12 Nov 2019

Notice of Annual General Meeting/Proxy Form incl. Annual Report

ANP – Appendix 4G

ANP – Appendix 3B – 29 Oct 2019

Neuromuscular Drug Development Summit Poster Presentation

ANP – Appendix 4C – 30 Sept 19_final

ANP to present at Neuromuscular Drug Development Summit in USA

ANP – Appendix 3B – 04 Oct 2019

Positive Preliminary results from ATL1102 for DMD Phase II trial

ATL1102 for DMD commencement of European regulatory interactions

Appendix 4E

EAP Update_ATL1103

ATL1102 Phase II clinical trial in DMD update

Appendix 4C – 30 June 2019

Conference Presentation June 2019

Updated Investor Presentation

ATL1102 Phase II clinical trial in DMD final enrolment

Employee Share Ownership Plan

Appendix 4C – 31 March 2019

ATL1102 Phase II clinical trial in DMD update

Completion of $1.6M placement

Placement to Accelerate Development of ATL1102 in DMD

Appendix 4D

ASX 19_30 Jan_ANP – Appendix 4C – 31 Dec 18

ASX 19_23 Jan_Updated Company Presentation

ASX 19_ 18 January ATL1102 Phase II clinical trial in DMD update_Final

Menu